Email updates

Keep up to date with the latest news and content from Diagnostic Pathology and BioMed Central.

Open Access Highly Accessed Open Badges Research

EGFR, CD10 and proliferation marker Ki67 expression in ameloblastoma: possible role in local recurrence

Azza Abdel-Aziz* and Maha M Amin

Author Affiliations

Pathology Department, Faculty of medicine, Mansoura University, Egypt

For all author emails, please log on.

Diagnostic Pathology 2012, 7:14  doi:10.1186/1746-1596-7-14

Published: 2 February 2012



Ameloblastoma is an odontogenic neoplasm characterized by local invasiveness and tendency towards recurrence.


Studying the role played by EGFR, CD10 and Ki67 in the recurrence of ameloblastoma.


This study was carried out on 22 retrospective cases of mandibular ameloblastoma from the period from Jan 2002 to Jan 2008 with follow up period until Jan 2011 (3 to 8 years follow up peroid). Archival materials were obtained from pathology department, Mansoura university. Paraffin sections of tumor tissue from all cases were submitted for routine H&E stains and immunohistochemistry using EGFR, CD10 and Ki67 monoclonal antibodies. Statistical analysis using of clinical data for all patients, tumor type, EGFR, CD10 and Ki67 expression in relation to recurrence were evaluated.


Among the 22 cases, 10 cases were males and 12 were females with sex ratio 1:1.2. Age ranged from 34 to 59 years old with a mean age 44.18 year. Five cases showed local recurrence within studied period and proved by biopsy. No statistically significant relation was found between local recurrence and patient age, tumor size, tumor type, EGFR expression. There was a significant relation between CD10 expression as well as Ki67 labelling index and recurrence (P value = 0.003, 0.000 respectively).


Evaluation of CD10 and Ki67 status together with conventional histological evaluation can help in providing more information about the biologic behavior of the tumor, while EGFR could be a target of an expanding class of anticancer therapies.

Since ameloblastomas are EGFR-positive tumors, anti-EGFR agents could be considered to reduce the size of large tumors and to treat unresectable tumors that are in close proximity to vital structures.

Virtual Slides

The virtual slide(s) for this article can be found here: webcite

Ameloblastoma; EGFR; CD10; Ki67 and recurrence